CoChat

Health‐economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK

Open access
Roze, S., Valentine, W. J., Zakrzewska, K. E., Palmer, A. J. · 2005 · Diabetic Medicine
Cited by 96

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Objectives The aim of this study was to project the long‐term costs and outcomes of continuous subcutaneous insulin infusion (CSII) compared with multiple daily injections (MDI) in patients with Type 1 diabetes in the UK. Methods The CORE Diabetes Model is a peer‐reviewed, validated model which employs standard Markov/Monte Carlo simulation techniques to describe the long‐term incidence and progression of diabetes‐related complications. It was used to simulate disease progression in a cohort of patients with baseline characteristics taken from published UK studies (mean age 26 years, duration of diabetes 12 years, mean HbA 1c 8.68%). Direct costs for 2003 were calculated from a third‐party payer perspective. Discount rates of 3.0% per annum were applied to costs and clinical outcomes. Results Treatment with CSII was associated with an improvement in mean quality adjusted life expectancy (QALE) of 0.76 ± 0.19 years compared with MDI (12.03 ± 0.15 vs. 11.27 ± 0.14 years). Mean direct lifetime costs were £19 407 ± 1727 higher with CSII treatment compared with MDI (£80 511 ± 1257 vs. £61 104 ± 1249). This produced an incremental cost‐effectiveness ratio (ICER) of £25 648 per quality‐adjusted life year (QALY) gained with CSII vs. MDI. The results were most sensitive to variation in hypoglycaemia rates and altering improvements in HbA 1c associated with CSII therapy compared with MDI. Conclusions Improvements in glycaemic control associated with CSII over MDI led to improved QALE owing to reduced incidence of diabetes‐related complications. CSII was associated with an ICER of £25 648 per QALY gained vs. MDI, representing good value for money by current standards in the UK. Diabet. Med. (2005)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2005.01576.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 96

Metadata

Authors
Roze, S., Valentine, W. J., Zakrzewska, K. E., & Palmer, A. J.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2005-08-15
Volume
22
Issue
9
Pages
1239-1245
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2017930048
Cited by
96
References
2
FWCI
4.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Health‐economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. https://app.cochat.ai/papers/10.1111/j.1464-5491.2005.01576.x
The paper
Roze, S., Valentine, W. J., Zakrzewska, K. E., & Palmer, A. J. (2005). Health‐economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2005.01576.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.